UniQure announced plans to submit its gene therapy for Huntington's disease to the FDA for approval in Q3, following a recent FDA meeting that supported accelerated approval based on a three-year Phase 1/2 study. This marks a reversal from earlier FDA criticism under former Commissioner Marty Makary, who had questioned the trial data and demanded a placebo-controlled study. UniQure's therapy, which slows disease progression by 75%, was previously challenged due to ethical concerns about sham brain surgery controls. The FDA now agrees to an accelerated approval pathway with a commitment from UniQure to conduct a follow-up study comparing the therapy to standard care. Shares surged 70% on the news, highlighting renewed investor confidence.
Veea Inc. has announced the commercial release of VeeaONE, a full-stack AI infrastructure platform that integrates edge-to-cloud hardware and software. The platform supports VeeaWare middleware on NVIDIA Jetson and x86/Arm servers, enabling secure, l...
Virtuals Protocol has introduced customizable tokenized indexes on the Robinhood Chain, allowing users to combine multiple assets into a single token. This innovation enables users to create and manage their own asset baskets and earn fees when other...
US spot Bitcoin ETFs saw net inflows of $107.8 million on Wednesday, while Ethereum ETFs attracted $53.8 million, signaling renewed institutional interest in crypto funds. Since their launch in January 2024, Bitcoin ETFs have accumulated over $51 bil...
Kaia has signed a strategic partnership with Xilo Labs to integrate Mochi, an onchain asset management platform, into Kaia's ecosystem. This collaboration allows users to invest stablecoins into diversified portfolios backed by tokenized real-world a...
Bitcoin's price surged to nearly $65,000 following softer-than-expected U.S. inflation data for June, easing fears of Federal Reserve rate hikes. However, on-chain data reveals two main groups of investors—long-term holders who bought near last year'...
